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Steroid binding to Autotaxin links bile salts
and lysophosphatidic acid signalling
Willem-Jan Keune1, Jens Hausmann1,*, Ruth Bolier2,*, Dagmar Tolenaars2, Andreas Kremer2,
Tatjana Heidebrecht1, Robbie P. Joosten1, Manjula Sunkara3,4, Andrew J. Morris3,4, Elisa Matas-Rico5,
Wouter H. Moolenaar5, Ronald P. Oude Elferink2 & Anastassis Perrakis1

Autotaxin (ATX) generates the lipid mediator lysophosphatidic acid (LPA). ATX-LPA signalling is involved in multiple biological and pathophysiological processes, including vasculogenesis, ﬁbrosis, cholestatic pruritus and tumour progression. ATX has a tripartite active site,
combining a hydrophilic groove, a hydrophobic lipid-binding pocket and a tunnel of unclear
function. We present crystal structures of rat ATX bound to 7a-hydroxycholesterol and the
bile salt tauroursodeoxycholate (TUDCA), showing how the tunnel selectively binds steroids.
A structure of ATX simultaneously harbouring TUDCA in the tunnel and LPA in the pocket,
together with kinetic analysis, reveals that bile salts act as partial non-competitive inhibitors
of ATX, thereby attenuating LPA receptor activation. This unexpected interplay between
ATX-LPA signalling and select steroids, notably natural bile salts, provides a molecular basis
for the emerging association of ATX with disorders associated with increased circulating
levels of bile salts. Furthermore, our ﬁndings suggest potential clinical implications in the use
of steroid drugs.
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A

utotaxin (ATX) is a secreted lysophospholipase
D (lysoPLD) that produces the bioactive lipid lysophosphatidic acid (LPA) from extracellular lysophospholipids, predominantly lysophosphatidylcholine (LPC)1,2. ATX is a
unique member of the ectonucleotide pyrophosphatase/
phosphodiesterase (ENPP) family of enzymes that hydrolyse
phosphodiester bonds in various substrates, including nucleoside
triphosphates, lysophospholipids and choline phosphate esters3.
The bioactive product of ATX, LPA, acts on six distinct
G protein-coupled receptors (LPA1–6) that activate multiple
signalling pathways4. The biological outcome of ATX-LPA
signalling is remarkably diverse, depending on LPA receptor
expression patterns and tissue context, and includes the
stimulation of cell migration, proliferation and survival4–6. In
pathophysiology, ATX-LPA signalling has been implicated in
tumour progression, pulmonary ﬁbrosis, neuropathic pain,
cardiovascular disease and cholestatic pruritus, making the
ATX-LPA signalling axis an attractive therapeutic target7.
Crystal structures of ATX8,9 (ENPP2) revealed a catalytic
domain with a bimetallic active site adjacent to a catalytic
threonine. Substrate binding takes place in a shallow hydrophilic
groove that accommodates nucleotides as well as the glycerol
moiety of lysophospholipids, and in a deep hydrophobic pocket
binding the lysophospholipid acyl chain. In addition, the catalytic
domain together with the ﬁrst of two somatomedin-b (SMB)
domains, form a tunnel adjacent to the active site (Fig. 1a,b).
The function of this unique tunnel, which is absent in other
ENPP family members like ENPP1 (refs 10,11), remains
enigmatic. One hypothesis based on structural and mutagenesis
data suggests that the tunnel serves to deliver LPA to its cognate
G protein-coupled receptors (GPCRs)9. Recent structural analysis
shows that access to the LPA1-binding pocket occurs from the
extracellular space12, in contrast to the proposed access route of
the related lipid mediator sphingosine 1-phosphate (S1P) to its
receptor S1P1 (ref. 13). ATX isoforms have afﬁnity for cell-surface
integrins8 and heparan sulphate proteoglycans14. In addition,
kinetic analysis revealed that the half-time of the ATX:LPA
complex is several minutes15, allowing ATX:LPA to diffuse and
possibly recognize cell surface receptors, bringing the LPA
product closer to the cell membrane. Collectively, these
observations place ATX at the centre of an intrinsic network of
interactions that could explain its extensive roles in diverse
physiological and disease processes. Until now, no physiological
regulators of ATX activity have been identiﬁed.
Our on-going studies of ATX structure and catalytic mechanisms reveals that recombinant ATX contained steroids bind to the
tunnel. We discover that binding of at least one class of steroids,
bile salts, modulates ATX activity. Our ﬁndings reveal an

a

Tunnel

unexpected novel interplay between LPA and bile salts, and
possibly other steroids, and offer testable hypotheses on the
function of the ATX-LPA signalling axis in various physiological
contexts.
Results
ATX binds steroids in its tunnel. During the course of our
structural investigation of the ATX catalytic mechanism, we
obtained a 1.6-Å resolution structure of ATX (Table 1). Following
structure reﬁnement, some residual density in the tunnel became
apparent (Fig. 2a,b). The density was compatible with the fourring system bearing two axially oriented methyl groups, characteristic of steroid moieties. Indeed, modelling of cholesterol in
the density yielded a nearly perfect ﬁt (Fig. 2c). To explain
remaining difference density, adjacent to the C7 position of the B
ring, we modelled 7a-hydroxycholesterol (7HCS, Fig. 2d,e).
Notably, when we determined the ﬁrst ATX structure8 (2XR9)
at 2.05 Å resolution, we have noted that ‘residual electron density
occupies this tunnel, probably indicating the presence of a
molecule that we were unable to model (possibly a lipid acquired
from the growth medium)’. When we re-examined the maps
corresponding to that structure, with the hindsight that the
residual electron density could be 7HCS, it was indeed trivial to ﬁt
a 7HCS moiety to that residual density in the tunnel
(Supplementary Fig. 1). This indicated that 7HCS has always
been present in our protein preparations, and it is certainly a
bound ligand in the 2XR9 ATX structure, which we were unable
to identify at the time. Indeed, the presence of cholesterol
(B15%), hydroxysterols (B80%) and 7HCS speciﬁcally (B75%
of total hydroxysterols and B60% of the total) at near
stoichiometric levels to ATX, in several preparations, was
conﬁrmed by mass spectrometry (Table 2 and Supplementary
Fig. 2). The mass spectrometry data also suggest that the
predominant 7HCS species is the a epimer. The 7HCS structure
and the revised 2XR9 structure strongly suggest that 7HCS is
most likely the only bound molecule, albeit the exact nature of the
aliphatic chain could not be uniquely identiﬁed.
The steroid moiety is oriented away from the active site with
the 3-OH group facing the solvent on the opposing surface of the
molecule. The steroid rings are well packed, with the conserved
Trp254, Trp260 and Phe274 likely participating in p–p interactions. The 7-OH group is clearly only in a single anomeric
conﬁguration (a) as suggested by the mass spectrometry data; the
preference is explained by a hydrogen bond to the Nz atom of
Trp260. The selectivity towards the 7-OH substituted steroid is
notable, as a Protein Data Bank (PDB) search suggests this is the
only example of speciﬁc hydroxysterol recognition by a carrier
protein.

b
Tunnel LPA

Figure 1 | The tunnel of ATX. (a) A cartoon representation of the domain structure of ATX combined with a transparent surface highlighting the position of
tunnel; the SMB domains are coloured in pink and magenta, the PDE domain in green, the NUC domain in blue, the lasso loop wrapping around the NUC
domain in orange and the short loop connecting the SMB domains to the PDE domain in cyan; the zinc ions are shown as spheres; a yellow background
highlights the tunnel site, (b) the same cartoon model, with bound LPA18:1 (PDB:3NKP) and a yellow circle designating the tunnel site. All structural images
were generated using PyMOL (http://www.pymol.org) or CCP4mg48.
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Table 1 | Crystallographic data.

PDB identiﬁer
Data collection
Space group
Cell dimensions
a, b, c (Å)
a, b, g (°)
Resolution (Å)*
Rmerge (%)
CC1/2
Average I/sI
Completeness (%)
Redundancy
Reﬁnement
Resolution (Å)
No. of reﬂections
Rwork/Rfree
No. of atomsw
Protein þ carbohydrates
Ligand þ metal ions
Waters and others
B-factors (Å2)
All
Protein þ carbohydrates
Ligand þ metal ions
Water and others
R.m.s. deviationsz
Bond lengths (RMSZ/RMSd)
Bond angles (RMSZ/RMSd)

ATX þ 7HCS
5DLT

ATX þ TUDCA
5DLV

ATX þ LPA þTUDCA
5DLW

P1

P1

P 21 21 21

53.67, 63.48, 70.72
98.72, 105.80, 99.97
44–1.60 (1.63–1.60)
7.5 (59.8)
1.00 (0.44)
6.7 (0.8)
92.1 (88.9)
2.0 (1.9)

62.88, 77.83, 92.44
83.84, 79.29, 77.08
47–2.00 (2.03–2.00)
11.5 (122)
0.99 (0.34)
5.6 (0.8)
97.9 (92.0)
3.6 (3.5)

63.20, 93.05, 149.68
90,90,90
46–1.80 (1.83–1.80)
15.2 (240)
1.00 (0.26)
8.6 (1.0)
99.8 (99.3)
5.9 (5.8)

44–1.60
99938
17.1/19.6

47–2.00
108586
19.3/22.7

44–1.80
78197
18.8/21.6

6542
34
613

12896
224
694

6399
68
341

29
29
26
34

36
36
39
35

33
33
56
35

0.461/0.013
0.658/1.450

0.483/0.010
0.644/1.435

0.487/0.010
0.664/1.466

ATX, Autotaxin; LPA, lysophosphatidic acid; PBD, Protein Data Bank; RMS, root-mean-square; TUDCA, tauroursodeoxycholate; 7HCS, 7a-hydroxycholesterol.
*Highest resolution shell is shown in parenthesis.
wAlternate conformations are counted as multiple atoms.
zAs given by REFMAC for all bonds and angles.

Bile salts bind ATX and inhibit LPA production. As sterols
were not present during ATX puriﬁcation, while ATX was
selective for a 7a-substituted steroid presumably acquired from
the cells and/or cell culture medium, we went on to investigate
how distinct steroids may modulate ATX activity (Fig. 3).
Hydroxysterols like 7HCS or 7a,25-dihydroxycholesterol,
as well as various other steroids (testosterone, dexamethasone,
prednisolone), had no effect on ATX-mediated LPC hydrolysis
(Fig. 3b and Supplementary Fig. 3). Strikingly, however, the
conjugated bile salt tauroursodeoxycholate (TUDCA) inhibited
ATX activity with an apparent IC50 of 10 mM (Fig. 3c). Structure–
activity relationship studies using bile salts with different
substitutions of the steroid rings and different conjugates of the
acidic tail, revealed that: (i) bile salts with the C7 hydroxyl in the
a-conﬁguration (taurochenodeoxycholate) or in the b-conﬁguration (TUDCA) inhibit ATX activity with similar potency
(Fig. 3 c,d); (ii) the presence of a hydroxyl in C12 of the C ring,
either in the presence of the C7 hydroxyl (that is, taurocholate) or
in the absence of the C7 hydroxyl (that is, taurodeoxycholate)
abrogate the inhibitory activity of TUDCA (Fig. 3e,f); and (iii) the
conjugation of the acidic tail did not signiﬁcantly change potency,
as shown by using glycochenodeoxycholate (which is conjugated
to glycine instead of taurine) or ursodeoxycholate (lacking
conjugation; Fig. 3g,h).
To understand the selectivity of bile salts on ATX activity, we
co-crystallized ATX with TUDCA and determined the structure
to 2.0 Å resolution (Table 1). Following molecular replacement
and model adjustment, there was a clear difference electron
density in the tunnel, markedly different from the density for
7HCS (Fig. 4a,b). Owing to the reduction of the C5–C6 double

bond of the steroid B-ring, the four-ring system in bile salts is no
longer planar, but adopts an L-shaped conformation (Fig. 4b). In
comparison with the 7HCS placement, the steroid moiety of
TUDCA has ‘slid’ inside the tunnel by about 2.5 Å towards the
active site (Fig. 4c,d). This movement ‘aligns’ the D-ring better
with Phe274, likely resulting to more favourable p–p interactions.
The Nz of Trp260 now forms a hydrogen bond with the 3-OH
group of the A-ring, instead of the 7-OH that has moved away. In
addition, the conserved His251 ﬂips towards the tunnel exit,
acting as a ‘lid’. Overall, the ring placement indicates a stronger
interaction of TUDCA compared with 7HCS in the tunnel. Given
that the tunnel may serve as an LPA exit route9, this observation
might provide a mechanism for the inhibitory activity of
TUDCA. Unlike the steroid moiety, the acidic tail is not very
well resolved in the electron density. Further reﬁnement allowed
modelling of three district conformations of the TUDCA acidic
tail (Supplementary Fig. 4a,b).
Strikingly, structural alignment of the TUDCA structure with
the 7HCS structure or the native structure (2XR9), showed that
the SMB domains move ‘outwards’ to accommodate TUDCA in
the tunnel (Supplementary Fig. 4c); a movement of the ATX SMB
domains relative to the catalytic core has not been observed
before. Thus, TUDCA binding induces a conformation change,
which may have implications for SMB domain interactions and
binding site dynamics.
The observed multiple conformations of the acidic tail,
contrasting with the well-deﬁned binding of the bile salt steroid
moiety, agrees well with the structure–activity data, and
prompted us to examine further the inhibition mechanism of
bile salts towards ATX.
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Tunnel

b
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26
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OH

A
4

10
5

BH
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20
17

D
14

24
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OH

Figure 2 | 7a-OH steroids are bound in the tunnel of ATX. (a) A zoom-in
to the model with difference density (mFo  DFc) shown as a green
wireframe model before any ligand or water placement contoured at 3.5
RMS highlighting the unexplained density in the tunnel. (b) The model is
rotated about 90° along the vertical display axis to show the same
difference density map. (c) The model is shown in the same orientation as
before after including a sterol molecule in the reﬁnement; the resulting
2mFo  DFc map is shown in blue at 1.2 RMS and the difference map in
green still indicates a missing atom. (d) The electron density maps after full
reﬁnement including the 7a-hydroxycholesterol molecule; all difference
density peaks have disappeared. (e) The molecular structure of
7a-hydroxycholesterol showing all atom and ring names.
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Bile salts are non-competitive inhibitors of LPC hydrolysis.
Testing the inhibitory effect of different TUDCA concentrations
against increasing concentrations of LPC, showed a reduction in
Vmax with no signiﬁcant change in the kM of the reaction
(Fig. 5a); consistently, kinetic modelling conﬁrmed that a competitive model has a probability of o0.01% to be correct (see the
Methods for details and equations). As TUDCA is a partial
inhibitor of ATX (Fig. 3b), we used a partial mixed inhibition
model to explain the kinetic data (see the Methods for details).
Kinetic modelling suggested that while TUDCA has an appreciable KI of 9±3 mM, even at saturating concentrations B40% of
ATX activity towards LPC is retained. Crucially, mathematical
modelling indicated that TUDCA is a noncompetitive inhibitor,
implying that LPC or LPA can co-exist in a ternary complex with
ATX.
To test this hypothesis, we crystallized a complex of ATX,
TUDCA and LPA and we determined a structure of this ternary
complex to 1.8 Å resolution (Table 1). In this complex, TUDCA is
well deﬁned in density (Supplementary Fig. 5) and the steroid
moiety lies in the tunnel (Fig. 5b–d), but the conjugated tail is in a
single well-deﬁned conformation pointing away from the active
site (Fig. 5e). LPA(18:1) binds in a similar pose as shown
earlier for mouse ATX9 (3NKP); whereas the glycerol moiety is
well deﬁned in density, the aliphatic tail is less well deﬁned
(Supplementary Fig. 5) and likely exists in multiple
conformations. This structure reveals the molecular basis of
TUDCA action as a non-competitive inhibitor, and conﬁrms that
tunnel blockade by the bile salt, rather than active site destabilization, underlies its inhibitory activity.
These observations reinforce the hypothesis that the tunnel
serves as a product exit route9; partial inhibition by bile salts
further suggests that the tunnel is an alternate but not obligatory
exit route for LPA release. It is important to note that, although
TUDCA acts as an inhibitor over a wide variety of LPC substrates
with different aliphatic tails (Supplementary Fig. 6a–d), TUDCA
did not inhibit the hydrolysis of nucleotide substrates
(Supplementary Fig. 6e). This further supports the hypothesis
that TUDCA acts by blocking LPA exit through the tunnel.
Moreover, TUDCA completely inhibited hydrolysis of the
ﬂuorescent lysolipid analogue FS3 (ref. 16; KI ¼ 1.4 mM,
Supplementary Fig. 6f) in a competitive manner (see the
Methods for details). Although it is unknown how ATX binds
FS3, it seems likely that one of the two FS3 acyl chains with the
attached ﬂuorophore is accommodated in the ATX tunnel,
making TUDCA-mediated inhibition for FS3 competitive in
nature. We conclude that the tunnel is an allosteric site that binds
bile salts to reduce LPA production rates, most likely by slowing
down product release.
Bile salts attenuate ATX function ex vivo and in situ. To
validate that bile salts act as allosteric inhibitors in a physiological
setting, we examined their effect on modulating LPA production
in human serum. Consistent with our in vitro ﬁndings, TUDCA
inhibits endogenous ATX activity in human serum ex vivo

Table 2 | Mass spectrometry analysis of ATX.

ATX
Cholesterol
Total DMG hydroxycholesterol
7-a Hydroxycholesterol

pmol
2.4
0.35
1.95
1.48

Ratio
1.0
0.15
0.81
0.62

ATX, Autotaxin.
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Figure 3 | Activity of ATX in the presence of selected steroids. (a) A visual guide to the annotations used for indicating speciﬁc functional groups in the
bile acids chemical formulas (b–h) Inhibition of lysoPLD ATX activity measured as released choline by LPC(18:1) hydrolysis in the presence of speciﬁc bile
salts with different steroid moiety hydroxylation patterns and acidic tail conjugations. The 12-OH substitution is not tolerated while the conjugation does
not affect activity. The grey, blue and red circles highlight the hydroxylation of the steroid backbone; the orange and blue boxes highlight the conjugation
partner. The error bars represent s.e.m. from triplicate experiments. Conc, concentration.

(Fig. 6a) with an apparent IC50 of B30 mM. Also in serum,
TUDCA behaves as a partial inhibitor, leaving B40%
residual activity. Next, we examined the ability of bile salts to
modulate ATX-LPA signalling, by examining their effect on
ATX-dependent LPA receptor activation in cultured cells
(in situ), using agonist-induced LPA1 receptor internalization as
readout17,18. As shown in Fig. 6b,c, at low LPC substrate levels,
TUDCA reduces ATX-mediated LPAR1 endocytosis in HeLa
cells, consistent with reduced and/or delayed LPA production and
delivery.

Discussion
Our ﬁnding that bile salts such as TUDCA and glycochenodeoxycholate act as allosteric inhibitors of ATX lysophospholipase D
activity, suggests that ATX may interact with steroids in vivo.
Under pathological conditions, notably cholestasis, bile salt
concentrations can reach 4100 mM in the blood stream19.
Thus, the observed binding constants of bile salts to ATX
(B10 mM) suggest that bile salts are likely to modulate ATX
activity under natural conditions. As the lifetime of the ATX:LPA
complex is relatively long (tens of seconds15) allowing the
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a

b

c
Trp254
His251

Phe274
Trp260

d
His251

Trp254

Phe274
Trp260
Figure 4 | The bile salt TUDCA binds the tunnel of ATX. (a,b) The
2mFo-DFc electron density map before ligand placement is contoured at 1.2
RMS and shown as a blue wireframe model in two views; TUDCA (orange
carbons; oxygens in red, sulfur in yellow and nitrogen in blue) is shown
as a stick model. (c,d) Comparison of the binding of TUDCA and
7a-hydroxycholesterol; Trp260 forms a hydrogen bond (dotted line) with
the 3a-OH of TUDCA (in orange), whereas it forms a hydrogen bond with
7a-OH of the hydroxycholesterol (in green). In the TUDCA-bound
structure, His251 ﬂips towards the A-ring, whereas in both structures
Trp260 and Phe274 pack against the steroid ring system.

complex to diffuse over a distance of B65 mm before dissociating,
bile salt-mediated stabilization of the ATX:LPA complex could
enable further spreading of the LPA signal and allow LPA-loaded
ATX to interaction with integrin receptors8 or heparan
proteoglycans14 in a more productive manner.
Modulation of ATX activity by bile salts is an intriguing ﬁnding
given that cholestatic itch is accompanied by a signiﬁcant increase
in serum ATX activity19. In addition, intradermal injection of
LPA in mice leads to a transient but signiﬁcant increase in scratch
behaviour, strongly suggesting that LPA produced by ATX
initiates or potentiates itch19. As cholestasis is characterized by
accumulation of bile salts in the circulation, this is at ﬁrst sight
contradictory to our ﬁndings. However, delaying LPA release by
prolonging the lifetime of the ATX:LPA complex, might have
stimulatory effects in select cells, such as sensory neurons
involved in itch perception.
6

In the context of cholestatic disease, it is noteworthy that
UDCA is often used for the treatment of women with cholestasis
of pregnancy (ICP), which develops in B1% of pregnant women
during the third trimester of pregnancy, to relieve itch20. As ATX
activity in the serum of these patients is signiﬁcantly increased
and serves as a diagnostic marker21, our results suggest that the
antipruritogenic effect of UDCA may be attributed, at least in
part, to inhibition of plasma ATX activity. This notion is also
supported by our ﬁnding that TUDCA inhibits serum ATX
ex vivo (Fig. 6a).
In addition, UDCA is the only FDA-approved drug for the
treatment of primary biliary cholangitis, a disorder that leads to
progressive cholestasis and is often associated with chronic itch22.
Moreover, TUDCA has been shown to alleviate symptoms of
arthritis in rats23; interestingly, ATX has been implicated in the
pathogenesis of modelled arthritis24. Anti-inﬂammatory effects of
UDCA and its conjugated derivatives have also been recognized
in other non-hepatic disorders in which ATX could play a role,
such as neurite growth impairment25, colitis26 and neovascularization27. Furthermore, UDCA has been explored as a drug to
alleviate symptoms of several neurodegenerative diseases
including ALS, Parkinson’s disease and Huntington’s28;
although molecular mechanisms that implicate an apoptotic
function and ER stress relief have been suggested29,30, the
mechanism of action of UDCA and its derivatives remains an
active ﬁeld of research. The hypothesis that the therapeutic effect
of ursodeoxycholates is partially achieved also by unwittingly
interfering with ATX function and LPA signalling warrants
further investigation.
Various steroidal and non-steroidal agonists of the bile salt
receptors TGR5 and FXR are being investigated as candidate
drugs for the treatment of chronic liver disease, hepatocellular
cancer and extrahepatic inﬂammatory and metabolic diseases31.
More speciﬁcally developments have targeted obesity, type 2
diabetes, hypertriglyceridaemia and atherosclerosis32. In addition,
obetichocolic acid is being evaluated in clinical trials as a
treatment for non-cirrhotic, non-alcoholic steatohepatitis33. The
interaction of ATX with bile salts, even regardless of their ability
to modulate LPA signalling, might be important for delivering
such drugs to their cognate receptors, much as already proposed
for ATX and LPA7,9.
Oxysterols, which clearly bind ATX but did not appear to
change ATX activity in vitro, using LPC(18:1) as substrate, have
emerged as signalling molecules linked to breast cancer
pathophysiology34. We cannot exclude the possibility that
certain oxysterols (or other steroids) might be affecting the
processing of other physiologically relevant unsaturated
LPC species with longer acyl chains (that are not available for
testing).
LPA binds to albumin. How the protein-bound LPA pool, the
bio-active LPA pool (which can also be the ATX-bound LPA)
and the LPC substrate pool are correlated is poorly understood.
Recently, Hla and co-workers have shown that altering the
balance of apolipoprotein M and free S1P inﬂuences lymphopoiesis and neuroinﬂammation35. By analogy LPA, and
steroids might affect the balance between plasma protein and
ATX-bound pools of LPA, selectively promoting or inhibiting
LPA signalling.
Finally, steroids speciﬁc for the ATX tunnel may offer an
alternative strategy for developing ATX inhibitors as partial
inhibitors might prove of importance. In addition, blocking the
ATX tunnel by molecules that slow down LPA release, might
even promote LPA signalling, by allowing more efﬁcient delivery
of LPA to its receptors.
In conclusion, our study reveals a previously unknown
interplay between ATX-mediated LPA production and bile salts
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Figure 5 | TUDCA acts as a non-competitive inhibitor of LPC hydrolysis. (a) ATX lysoPLD activity with no inhibitor (black line and symbols) and with
three concentrations (conc) of TUDCA (orange lines and symbols) as function of LPC(18:1) substrate conc. Modelling of all data (see the Methods for
details) indicate that TUDCA acts as a partial noncompetitive inhibitor, with a Ki of 9±3 mM and residual activity of B40% towards LPC. (b) A cartoon of
the ATX structure with bound TUDCA (orange carbons) in the tunnel and LPA (blue carbons) in the pocket, both shown as space ﬁlling models. (c,d) A
zoom-in view showing the molecular surface of ATX at the TUDCA- and LPA-binding sites empty (c) and with bound TUDCA and LPA (d) as space ﬁlling
models. (e) A zoom-in to a view along the tunnel axis, showing the characteristic L-shaped bile acid ring system and the bound LPA(18:1); the taurine tail
has moved away from the active site to make space for the LPA; the active site zincs are visible to the right as grey spheres.
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Figure 6 | Physiological effects of bile salts on human serum and LPA receptor activation. (a) Inhibition of lysoPLD activity is human serum
supplemented by TUDCA, measured as released choline by LPC(18:1) hydrolysis. The error bars represent s.e.m. from three different samples.
(b) Representative confocal images of untreated and TUDCA-treated HeLa cells transfected with GFP-LPA1; the number of GFP-LPA1-containing
endosomes is lower in TUDCA-treated cells. Scale bar, 10 mm. (c) Quantiﬁcation of LPA1 internalization shows that TUDCA reduces the number of
endosomes compared with untreated cells; error bars correspond to s.e.m. from 27 images in two independent experiments; ***Po0.001 according to
Student’s t-test.

acting as allosteric modulators of ATX activity, with potential
physiological and clinical implications.
Methods
ATX production and crystallization. ATX from rat (rATX) and human (hATX)
proteins were produced in HEK 293 Flp-In cells as described previously36. The
high-resolution crystals that contained 7HCS, rATX (3.5 mg ml  1) was ﬁrst
pre-incubated with 23.5 mg ml  1 heparin sulphate; 1 ml of this solution was then
mixed with 1 ml of reservoir solution containing 20% (w/v) PEG 3350, 0.1 M NH4I
and 0.3 M NaSCN. After 1 week, the ﬁrst crystals formed, to ﬁnally obtain a crystal
of 0.15  0.02  0.02 mm3. This unusually large crystal diffracted to high
resolution; although we did not investigate in detail why, these were some
of our best-diffracting crystals at the time. We believe that we obtained them

through the combination of a good protein preparation (the quality of protein
preps often vary), optimizing little practical details of ATX crystallization
(as this is done manually there is variation), and reducing the pH close to 6.0
due to the acidic heparin (which we measured at the end in the reservoir solution).
For co-crystallization of rATX with TUDCA, TUDCA was ﬁrst mixed in 10 M
excess with rATX (3.5 mg ml  1) and incubated for 30 min. For co-crystallization
of rATX with TUDCA and LPA(18:1) (Avanti Polar Lipids), rATX (3.5 mg ml  1)
was ﬁrst mixed with a 3 M excess of LPA(18:1) and 10 M excess of TUDCA,
and incubated for 30 min. In both cases, the best crystals were obtained
at room temperature (293 K) in a 24-well optimization screen (18–20% PEG
3350, 0.1–0.4 M NaSCN and 0.1–0.4 M NH4I) by mixing 1 ml of
protein:inhibitor solution and 1 ml of reservoir solution. All crystals were
vitriﬁed in cryoprotectant, which consisted of reservoir solution with the
addition of 20% (v/v) glycerol.
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Crystallographic data and methods. Structural studies were performed with
rATX. The X-ray diffraction data for the complexes were collected at ESRF on
beamlines ID29 (7HCS, TUDCA:LPA) and ID23 (TUDCA), respectively, at 100 K.
The crystallographic diffraction data were recorded on a PILATUS detector to
resolution of 1.60 Å for the 7HCS complex, 2.20 Å for the TUDCA complex and
1.80 Å for the TUDCA:LPA complex. All data were processed and integrated with
XDS37 and scaled with AIMLESS38. The structures were determined by molecular
replacement using PHASER39 with the structure of ATX (PDB entry 2XR9 (ref. 8))
as the search model. Model building and subsequent reﬁnement were performed
iteratively with COOT40, REFMAC5 (ref. 41) and PDB_REDO42.
The 7HCS structure was ﬁrst extensively reﬁned, before we attempted
modelling of cholesterol and then 7HCS, as described earlier. For the TUDCA
structure, TUDCA was initially modelled in a single conformation in one of the
two ATX molecules in the asymmetric unit; after reﬁnement, a second molecule
was modelled in the ATX molecule in the second asymmetric unit. After extensive
reﬁnement, the TUDCA moiety in the ﬁrst asymmetric unit was modelled in three
different conformations to account for residual difference density. Following that,
some neighbouring residues were also modelled in multiple conformations. In the
TUDCA:LPA complex, the TUDCA and LPA moieties were modelled directly in
the difference density map after initial reﬁnement. Structure validation was carried
out by MolProbity, and shows that 97% of all residues where within the
Ramachandran plot favoured regions for all three structures, while one residue was
an outlier; the clash score and the MolProbity43 score for all three structures belong
to the 100th percentile. Additional crystallographic parameters and model quality
indicators are summarized in Table 1. The structure models and experimental
diffraction data were deposited at the PDB under codes 5DLT for 7HCS, 5DLV for
the TUDCA complex and 5DLW for the TUDCA–LPA complex.
Structural alignment of the TUDCA structure with the 7HCS structure or the
2XR9 structure performed by RAPIDO44, suggested that an optimal alignment
should include two rigid bodies: the ﬁrst consisting of most of the SMB domains
(residues 56–100 and 110–120) and a loop of the phosphodiesterase domain
(275–284), and the second of the rest of the protein. Both rigid bodies are similar
between the two structures (root-mean-square (RMS) deviation 0.5 Å). However,
superposing on the second, larger, rigid body shows that the SMB domains have
an RMS deviation of 2.3 Å to each other, showing that they moved ‘outwards’ to
accommodate TUDCA in the tunnel.

Mass spectrometry analysis. Recombinant hATX preparations or buffer
controls were extracted using acidiﬁed organic solvents as reported previously
for lipid extractions from cells and tissues45 with inclusion of deuterium-labelled
cholesterol of oxysterol internal standards as detailed below. Samples were
evaporated to dryness and reconstituted in methanol for mass spectrometry
analysis.
Cholesterol and hydroxysterols were analysed using an AB Sciex 4000-Qtrap
hybrid linear ion trap triple quadrupole mass spectrometer in multiple reaction
monitoring mode connected to a Shimadzu HPLC. Cholesterol was analysed in
positive multiple reaction monitoring mode using a Machery Nagel Nucleodur
C8 gravity column, 5 mm, 125  2 mm2 with a ﬂow rate of 0.5 ml min  1. Solvent
A consists of 75/25 of methanol/water with 0.5% formic acid and 0.1% 5 mM
ammonium formate and solvent B consists of 99/1 of methanol/water with 0.5%
formic acid and 0.1% 5 mM ammonium formate. The cholesterol measurements
were conducted exactly as reported previously with quantiﬁcation accomplished by
reference to a deuterated internal standard45. Oxysterols were measured after
dimethylglycine (DMG) derivatization using an Agilent Zorbax Eclipse XDB-C18
column, 5 mm, 4.6  150 mm2 with a ﬂow rate of 0.5 ml min  1. Solvent A was 85%
methanol with 5 mM ammonium acetate and solvent B consisted of 80:20:2 of
chloroform/water/50 mM ammonium acetate. In brief, we obtained authentic
standards for 25-, 24-, 27, 7-a and 4-b OH cholesterol and deuterated 25-OH
cholesterol and prepared DMG derivatives exactly as previously described46. We
obtained product ion spectra from the doubly and singly charged DMG derivatives
of these compounds that were essentially identical to those reported previously
with some differences in product ion abundances that are likely attributable to
differences between our mass spectrometer system and that used by Jiang et al.46.
The DMG derivatives of these authentic standards were used in conjunction with
known information reported46 to develop mass spectrometry methods that
measure product ions that are common to these derivatives and ions that are
diagnostic of the particular oxysterols that were then used in selected reaction
monitoring mode HPLC-coupled tandem mass spectrometry assays using
chromatography methods that could separate these standards. Quantiﬁcation of
oxysterols was accomplished by reference to the deuterated 25-OH cholesterol
internal standard as explained below.
Cholesterol was detected in all ATX preparations analysed. Extracted ion
chromatograms for two precursor product ion pairs, which were used to detect and
quantify the deuterated cholesterol internal standard and ATX-associated
cholesterol, are shown in Supplementary Fig. 2, while Table 2 shows representative
data from one ATX preparation.
As reported by Jiang et al.46, bis-DMG derivatives of hydroxylated cholesterol
generate doubly charged molecular ions (m/z ¼ 287.3), which fragment to produce
protonated DMG (m/z ¼ 104.1) and production of singly charged mono-DMG
derivative ions (m/z ¼ 367.2). Further fragmentation/rearrangements of the
8

m/z ¼ 367.2 ion and its products through processes that are described in detail
by Jiang et al.46 generates ions of m/z ¼ 232.2 and m/z ¼ 255.2 that permit
discrimination of 7-OH cholesterol from other oxysterols. Accordingly, we
established a selected ion-monitoring mode HPLC LC MS/MS assay that
monitored these ion pairs. Supplementary Fig. 2 shows extracted ion
chromatograms for these four ion pairs identifying 7-OH cholesterol as the major
oxysterols associated with the ATX preparation we analysed. Jiang et al.46 also
reported relative differences in signal between the 387.2 and 255.2 ions that
discriminate the 7-a and 7-b OH cholesterol epimers. The relative intensities of
these ions in the data shown in the ﬁgure suggest that the major species is the 7-a
epimer, as also suggested by the structural data. Quantiﬁcation was accomplished
by comparing the integrated peak area for the 387.2/104.1 ion pair to that of the
corresponding ion pair from the deuterated 25-OH cholesterol internal standard.
That ATX preparation analysed contained 1.48 pmol of 7-OH cholesterol. Analysis
of extracted ion chromatograms for the precursor and product ions that are
common to the bis DMG derivatives of hydroxylated cholesterols with comparison
to the retention times of suggested that the preparation contained signiﬁcantly
lower levels of 24-, 25- and 27-OH cholesterols (0.47 pmol).
Biochemical assays and modelling of kinetic data. All biochemical studies were
performed with hATX. ATX lysoPLD activity was measured by choline release
from LPC47. 20 nM ATX (prepared from HEK 293 Flp-In cells) was incubated with
150 mM LPC(18:1) in a ﬁnal volume of 100 ml buffer containing 50 mM Tris,
pH 7.4, 0.01% Triton X-100, 50 mM CaCl2, 1 U ml  1 choline oxidase, 2U ml  1
horseradish peroxidase, 2 mM homovanilic acid (HVA). The relative amount of
released choline was measured by HVA ﬂuorescence in a 96-well plate (Corning).
Fluorescent intensity was determined at lex/lem ¼ 320/450 nm every 30 s for
90 min with a Fluorostar plate reader (BMG Labtech). Data analysis was performed
using GraphPad Prism.
Nucleotide phosphodiesterase activity was measured using pNP-TMP
(Sigma-Aldrich) as substrate in 50 mM Tris (pH 7.8), 140 mM NaCl, 5 mM KCl,
1 mM CaCl2, 1 mM MgCl2, 1 mg ml  1 fatty acid-free BSA. After addition of
recombinant ATX, the amount of liberated para-nitrophenolate (pNP) was
determined by the absorbance at 405 nm. The relative amount of released pNP was
determined by the absorbance at 405 nM every 30 s for 90 min with a Fluorostar
plate reader (BMG Labtech). Data analysis was performed using GraphPad Prism.
ATX activity against the FS3 substrate16 was measured by incubating 20 nM
ATX with the indicated range of FS3 in a ﬁnal volume of 50 ml in 50 mM Tris buffer
(pH 7.4) containing 0.2 mg ml  1 fatty acid-free BSA. Fluorescent intensity was
determined at lex/lem ¼ 485/520 nm every 30 s for 90 min with a Fluorostar plate
reader (BMG Labtech).
The experiments for determining IC50 for different bile salt inhibitors were
performed by adding the named bile salt and performing serial threefold dilutions;
for each bile salt concentration, the velocity of the reaction was monitored as a
function of time in the lysoPLD assay as described above. The linear part of the
reaction velocity was visually estimated (typically between 10 min and 1 h) and the
observed ﬂuorescence signal (described above) as a function of time was modelled
for all inhibitor concentrations simultaneously using the formula:


vmax  vmin
Ft ¼ F0 þ
þ vmin t
ð1Þ
ð1 þ cinh =IC50 Þ
where Ft is the observed ﬂuorescence signal relative to the choline product at each
time point (t), F0 is the background ﬂuorescence signal at the start of each
measurement, vmax and vmin are the ﬁtted values for the minimum and maximum
relative velocity (common for all inhibitor concentrations) and cinh is the
corresponding inhibitor concentration for each of the experiments.
At the same time, we have also derived an observed velocity (V) by linear
regression of the ﬂuorescence signal for each inhibitor concentration and modelled
that as a function of inhibitor concentration using the formula:
vmax  vmin
V¼
þ vmin
ð2Þ
ð1 þ cinh =IC50 Þ
for cross-checking the result of equation (1) and for creating the inhibition graphs
presented in various ﬁgures.
For initial comparison between competitive, uncompetitive and noncompetitive inhibition by TUDCA, using the LPC and the FS3 assays, we measured
the relative velocity for increasing LPC or FS3 substrate concentrations, for noinhibitor and for three different inhibitor concentrations. The relative velocity for
each data point was measured by linear regression as described above, and a
Michaelis–Menten curve was created for each inhibitor concentration. We then
used the following equations to describe each mode of inhibition:
V¼

Vmax cLPC
KM ð1 þ ci =Ki Þ þ cLPC

V¼



Vmax 1 þ ci =Ki cLPC
KM þ cLPC

V¼

Vmax cLPC
KM þ cLPC ð1 þ ci =Ki Þ

competitive inhibition

ð3Þ

noncompetitive inhibition

ð4Þ

uncompetitive inhibition

ð5Þ
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where V is the observed velocity and cLPC is the corresponding LPC concentration
for each data point, and ci is the inhibitor concentration for each curve; KM and
Vmax are the Michaelis–Menten constants and the estimated maximum velocity in
a relative scale, and Ki is the inhibition constant. Note that in equation (5) Ki
denotes the product of Ki (which is very high as the inhibitor actually does
not bind alone) and a constant that deﬁnes the apparent Ki of the ternary enzyme–
substrate–inhibitor complex.
The preferred model was estimated using pairwise comparisons and we chose
the best-ﬁtting model utilizing Akaike’s Informative Criteria to select the model
most likely to have generated the data. For the LPC hydrolysis data, the competitive
model had o0.01% probability to be correct when compared with either the
noncompetitive or the uncompetitive models, whereas the noncompetitive model
showed a moderate preference (75%) over the uncompetitive model (25%). For the
FS3 data, the competitive model had a probability of more than 99.99% to be
correct compared with other models.
For understanding the inhibition of LPC hydrolysis by TUDCA in further
detail, we used a partial mixed inhibition model deﬁned by the equation
V¼

Vmax cLPA ð1 þ PartÞ
KM ð1 þ CI =Ki Þ þ cLPA ð1 þ CI =aKi Þ

ð6Þ

where in addition to previous deﬁnitions that can be derived from equations (4–6),
we deﬁne Part as the partiality of the inhibition and a as an estimated constant that
determines mechanism: if a ¼ 1, the formula becomes identical to equation (4) and
the inhibition mode is noncompetitive; if a is very large, then the model approaches
a competitive model equation (3); if a is very small but greater than zero, the model
approaches an uncompetitive model.
For more robust ﬁtting, we also did an experiment where we varied the
inhibitor concentration for a ﬁxed amount of substrate, which we modelled using
an equation similar to equation (2):
V¼

Vmax
þ Vmax Part
ð1 þ cinh =Ki ð1 þ cLPA =KM ÞÞ

ð7Þ

equations (6) and (7) were ﬁt simultaneously, each in the data set(s) they describe
(with a relative scale factor applied to (7) to account for experiment differences),
with the parameters that are determined in both experiment (KM, Vmax, Ki, Part)
constrained to have identical values between experiments. This procedure allowed
a more robust ﬁt to determine all parameters from all available experiments. The
value of a reﬁned to 2.3, suggesting a noncompetitive inhibition model, where
TUDCA binds to ATX both in the absence and in the presence of LPC (or LPA),
albeit with a very modest twofold preference for the substrate-free protein.
All modelling was performed using the regression analysis tools within the
Graphpad/Prism software. The values of all derived parameters indicate mean
values as obtained by nonlinear regression analysis using the formulas listed above;
triplicate data were used as separate observations during the ﬁt; ±values indicate
the standard error of the mean.
Effects of bile salts in the ex vivo activity of ATX. An ATX choline release
activity assay (see above for details) was done with three different sera from normal
pregnant women (informed consent was obtained from all human participants;
study protocol approved by the Medical Ethical Committee of the Amsterdam
Medical Center). We chose those because ATX activity is relatively high without
increased serum levels of bile salts21. In place of puriﬁed ATX, 20 ml of serum were
added in a total assay volume of 150 ml), aiming to dilute the serum as little as
possible. Before starting the assay, the serum was pre-incubated with each indicated
TUDCA concentration (1:2 dilution) for 5 min. The indicated TUDCA
concentration is the ﬁnal concentration in the assay.
LPAR internalization assay. HeLa cells (obtained from American Type Culture
Collection) were grown in DMEM supplemented with 10% fetal bovine serum at
37 °C under 5% CO2. For LPA1 internalization studies, HeLa cells were transient
transfected with GFP-LPA1 plasmid using X-tremeGene 9 (Roche) reagent
according to the manufacturer’s instructions. At 10 h after transfection, the cells
were rinsed with SF-DMEM and incubated in the same medium for 16–24 h before
further treatments. Cells were treated with 0.1 mM LPC and 5 nM ATX or with
0.1 mM LPC and 5 nM ATX and 500 mM of TUDCA for 15 min. Coverslips were
ﬁxed with 4% paraformaldehyde for 10 min, washed twice with PBS and mounted
using Immu-Mount. Slides were examined on a Leica TCS-SP5 confocal microscope (  62 objective) and analysed using ImageJ software.
Cell culture and reagents. HEK 293 Flp-In (purchased from Invitrogen) and
HeLa cells were maintained in DMEM (Gibco, Life Technologies) supplemented
with 10% FCS (HyClone, Thermo Scientiﬁc) 2 mM glutamine, 100 U ml  1
penicillin and 100 mg ml  1 streptomycin (Gibco, Life Technologies). Choline
oxidase, HVA, horseradish peroxidase fatty acid-free BSA, Dexamethason,
PEG3350, NaSCN, NH4I, pNP-TMP (p-nitrophenyl thymidine 50 -monophosphate), taurochenodeoxycholic acid, taurodeoxycholic acid, glycochenodeoxycholic acid, ursodeoxycholic acid and LPA were purchased from Sigma-Aldrich.
LPC and 7a,25-dihydroxycholesterol from Avanti polar lipids. FS3 (LysoPLD/ATX
substrate) from Echelon and TUDCA from Calbiochem.
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